Hemato-Oncology Care During and After the COVID-19 Pandemic: Changes in Treatment Pathways, Patient Flow, and Durable...

The COVID-19 pandemic disrupted cancer care at every level of the clinical pathway, but its effect on hemato-oncology was distinctive because patients with hematologic malignancies often require urgent diagnosis, frequent hospital visits, transfusion support, intensive therapy, transplantation, cellular therapy, and infection-sensitive follow-up. This narrative review examines the pandemic as a disruption of hemato-oncology care delivery rather than only as a source of excess infection-related morbidity. It synthesizes evidence on diagnostic access, patient flow, treatment prioritization, infection-control circuits, day-hospital organization, inpatient access, telemedicine and hybrid follow-up, supportive care, vaccination, antiviral pathways, and high-complexity care delivery. The review distinguishes between temporary crisis restrictions, harmful diagnostic and therapeutic delays, and durable organizational adaptations that may remain relevant after the acute pandemic period. Evidence from cancer-service disruption studies, hemato-oncology outcome registries, telemedicine cohorts, and European hematopoietic cell transplantation activity surveys indicates that hemato-oncology care pathways were reorganized and selectively redirected during the pandemic, while selected components recovered through structured triage, protected circuits, remote review of stable patients, and individualized timing of transplantation and cellular therapy. The post-pandemic priority is not to preserve restrictive crisis practice, but to retain the organizational discipline generated by the crisis: protected diagnostic capacity, risk-stratified access, selective hybrid care, rapid infectious-risk assessment pathways, disciplined day-hospital scheduling, and reserved in-person capacity for unstable, procedure-dependent, or curative-intent patients. These adaptations should be maintained only insofar as they improve access, safety, and continuity of care without normalizing delayed diagnosis or undertreatment of aggressive disease.